Urinary pseudouridine excretion in myelomatosis

Area of Science:

• Biochemistry
• Oncology
• Clinical Medicine

Background:

• Multiple myeloma is a cancer of plasma cells.
• Accurate prognostic markers are crucial for managing multiple myeloma.
• Urinary psi (ψ) excretion is a potential biomarker.

Purpose of the Study:

• To investigate the relationship between urinary psi excretion and multiple myeloma tumor activity.
• To assess the prognostic value of urinary psi levels in multiple myeloma.

Main Methods:

• Quantification of urinary psi excretion in multiple myeloma patients and healthy controls.
• Comparison of urinary psi levels with established markers of tumor activity (serum paraprotein, serum beta 2-microglobulin, serum creatinine, urinary light chains).
• Correlation analysis between urinary psi levels and patient prognosis.

Main Results:

• Urinary psi excretion was independent of key indicators of tumor activity in multiple myeloma.
• Mean urinary psi levels were significantly higher in newly diagnosed multiple myeloma patients (40.7 ± 22.6 nmol·μmol ucr⁻¹) compared to controls (25.4 ± 4.8 nmol·μmol ucr⁻¹).
• Higher urinary psi levels at presentation were associated with a poorer prognosis, though this association diminished when stratified by serum beta 2-microglobulin levels.

Conclusions:

• Urinary psi is not directly correlated with tumor burden or activity in multiple myeloma.
• Urinary psi levels at diagnosis serve as a significant prognostic indicator for multiple myeloma.
• The prognostic utility of urinary psi is most pronounced when considered independently of serum beta 2-microglobulin.